Zoetis (ZTS) Share-based Compensation (2012 - 2026)
Zoetis' (ZTS) quarterly Share-based Compensation came in at $25.0 million in Q1 2026, up 47.06% year-on-year from $17.0 million in Q1 2025, and up 13.64% on a QoQ basis from $22.0 million in Q4 2025.
Zoetis (ZTS) Share-based Compensation (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Share-based Compensation data on file, last reported at $25.0 million in Q1 2026.
- On a quarterly basis, Share-based Compensation rose 47.06% year-over-year to $25.0 million in Q1 2026; TTM through Mar 2026 was $91.0 million, a 9.64% increase from a year earlier, with the FY2025 full-year figure at $83.0 million, up 12.16% from the prior year.
- Share-based Compensation for Q1 2026 stood at $25.0 million, up from $22.0 million in the prior quarter.
- Over the last five years, Share-based Compensation for ZTS reached as high as $41.0 million in Q2 2025 and fell as low as $3.0 million in Q3 2025.
- Historically, Share-based Compensation has averaged $17.9 million across 5 years, with a median of $17.0 million in 2023.
- On a YoY basis, Share-based Compensation climbed as much as 128.57% in 2022 and fell as far as 78.26% in 2022.
- Year by year, Share-based Compensation stood at $16.0 million in 2022, then grew by 6.25% to $17.0 million in 2023, then soared by 105.88% to $35.0 million in 2024, then slumped by 37.14% to $22.0 million in 2025, then grew by 13.64% to $25.0 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $25.0 million in Q1 2026, $22.0 million in Q4 2025, and $3.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 7.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.00 Mn |
| Mar 31, 2026 | 25.00 Mn |
| Dec 31, 2025 | 22.00 Mn |
| Dec 31, 2025 | 22.00 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 41.00 Mn |
| Jun 30, 2025 | 41.00 Mn |
| Mar 31, 2025 | 17.00 Mn |
| Mar 31, 2025 | 17.00 Mn |
| Dec 31, 2024 | 35.00 Mn |
| Dec 31, 2024 | 35.00 Mn |
| Sep 30, 2024 | 13.00 Mn |
| Sep 30, 2024 | 13.00 Mn |
| Jun 30, 2024 | 18.00 Mn |
| Jun 30, 2024 | 18.00 Mn |
| Mar 31, 2024 | 8.00 Mn |
| Mar 31, 2024 | 8.00 Mn |
| Dec 31, 2023 | 17.00 Mn |
| Dec 31, 2023 | 17.00 Mn |